Multiple abstracts presented at this week’s 24th European Academy of Dermatology and Venereology Congress in Copenhagen, illustrate the applications of multi-beam Optical Coherence Tomography (‘OCT’) technology.
Device company Michelson Diagnostics, developed the VivoSight scanner which uses Dynamic OCT imaging technology to visualise in real-time the structure of blood vessels beneath the surface of the skin, as well as the real-time effects of a therapeutic agent on this vasculature. The company says its breakthrough imaging development has the potential to assist dermatologists in the detection and prognosis of melanoma as well as monitoring the effectiveness of treatments for multiple skin conditions, including eczema, rosacea, psoriasis and wounds.
Here then are the clinical presentations from the EADV congress:
P0909 Diagnostic accuracy of optical coherence tomography in differentiating normal skin from non melanoma skin cancer, Olsen, J (Roskilde, Denmark)
P0921 Induced morphologic changes in skin vasculature imaged by speckle variance optical coherence tomography, Themstrup L (Roskilde, Denmark)
P1924 Speckle variance optical coherence tomography imaging of normal facial skin treated with Brimonidine Tartrate 0.33% gel visualises morphologic changes in skin vasculature, Themstrup, L (Roskilde, Denmark)
Microvascular remodelling related with tumour thickness and pattern of growth in melanoma and basal cell carcinoma: in vivo imaging with novel speckle variance optical coherence tomography, Nathalie de Carvalho (Modena, Italy)
Andy Hill, CEO of Michelson Diagnostics stated; “The data being presented at EADV demonstrates the broad applicability of the VivoSight OCT technology and the ability to produce images of the skin previously unavailable using existing scanning techniques. By integrating our Dynamic OCT technology with the VivoSight point-of-care scanner, we have significantly expanded our potential market segments.”
“In particular, our Dynamic OCT technology provides dermatologists with the capability to visualise blood vessel structures and changes to their appearance following a treatment in real time. We have already seen collaborators use this tool to help confirm the presence and stage of melanoma.”